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Abstract
Background: Adipokines have a wide range of effects and are linked to sepsis and septic shock. The aim of the
present study was to describe the changes in adipokine levels in septic patients in relation to patients’ preseptic
adipokine levels. Furthermore, we examined adipokines as prognostic markers.
Methods: Fourteen consecutive critically ill patients meeting the clinical criteria for severe sepsis or septic shock 3
days up to 1 month after major visceral surgery were enrolled prospectively. Plasma adipokines were measured
preoperatively, 1 and 4 days after diagnosis of severe sepsis or septic shock following elective surgery.
Results: Median plasma adiponectin levels were lowered and resistin and leptin levels elevated in sepsis compared
with preseptic plasma levels. MCP-1, C-reactive protein and white blood cell count were higher in septic compared
with preseptic patients.
Survivors had significantly higher preseptic adipokine levels than non-survivors. Adiponectin levels of survivors
decreased significant (on average by 33 %) at day one after onset of sepsis compared with preseptic levels. In
contrast, median adiponectin levels of patients dying during sepsis showed a slight increase (11 %). Median BMI
of survivors was 30 kg/m2, median BMI of non-survivors was 25, respectively.
Conclusions: Adipokine levels change during the course of sepsis. Higher preseptic adiponectin levels and
decreasing adiponectin levels after onset of sepsis are associated with survival of sepsis. Survival of overweight
and obese patients was higher than in normal weight patients. Changes in adiponektin levels could be a
prognostic marker for outcome of severe sepsis/septic shock following surgery.
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Abbreviations: APACHE II, Acute physiology and chronic health evaluation II; BMI, Body mass index; CRP, C-reactive
protein; IL, Interleukin; MCP-1, Monocyte chemoattractant protein-1; TNF-α, Tumor necrosis factor; WAT, White
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Background
Postoperative severe infection and sepsis remain a signifi-
cant cause of morbidity and mortality in intensive care
units. The complex dysregulated host response includes
uncontrolled inflammation and immune suppression and
is largely mediated by pro- and anti-inflammatory cyto-
kines. Among others, white adipose tissue (WAT) is
involved in the production of these pro- and anti-
inflammatory cytokines and the contribution of WAT to
the inflammatory reaction has already been demonstrated
[1]. Traditionally considered as a long-term energy storing
depot, WAT is now seen as an active endocrine organ that
releases a large number of bioactive mediators, mainly
adipokines (adipokines defined here as signaling protein-
aceous factors mainly produced or released by adipose
tissue) [2]. In septic patients as well as in morbidly obese
patients, the expression of these adipokines is altered.
Especially, the levels of pro-inflammatory adipokines are
elevated [3]. In morbidly obese patients, pro-inflammatory
adipokines appear to contribute strikingly to the ‘low-grade
inflammatory state’, setting up a cluster of metabolic aber-
rations including obesity-related metabolic/cardiovascular
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co-morbidities that collectively define the metabolic syn-
drome [4]. In critically ill and septic patients, adipokines
interact with inflammatory processes, and with coagula-
tion. Furthermore, they have an impact on insulin resist-
ance [5]. Thus, some of the metabolic abnormalities in the
metabolic syndrome share several common features with
those of sepsis and multiple organ dysfunction syndrome
of critical illness [6].
While morbid obesity is a risk factor for many diseases,
an inverse relationship between obesity and mortality has
been described in patients with heart failure, coronary
heart disease, diabetes, and septic shock [7, 8]. This
phenomenon is known as the ‘obesity survival paradox’. A
possible explanation among others could be an underlying
difference in adipokine-mediated metabolic and immune
response to acute illness [9]. Adipokines and their con-
tribution to the inflammatory reaction are still under
investigation.
Changes in adipokine levels in septic patients have
been described often [10], but the results are somewhat
contradictory. Compared with healthy controls, elevated
and lowered adiponectin levels have been reported in
septic patients [3, 11].
There have even been different results reported accord-
ing to whether levels rise or fall [12]. In part this could be
explained by the high variance of adipokine levels between
individuals in the absence of normal values. Changes in
adipokine levels in septic patients have been mostly re-
ported by comparison with a control group. Therefore,
the aim of the present prospective observational study was
to compare changes in adipokine profile in critically ill
patients with their preseptic profile.
Methods
In this study, 14 consecutive critically ill patients meet-
ing the clinical criteria for severe sepsis or septic shock
defined by Bone [13] after major abdominal surgery pro-
cedures were prospectively enrolled between January
2011 and May 2014. All patients undergoing abdominal
tumor surgery were asked to participate. 14 out of these
participating 548 patients developed severe sepsis or
septic shock. The Simplified Acute Physiology Score
(SAPS II) was used to define the severity of disease and
organ dysfunctions, respectively [14].
Blood samples were collected preoperatively in the
context of a routine blood draw, and 1 day after diagno-
sis of severe sepsis or septic shock and every third
additional day in sepsis at 7 a.m. in the fasting state
following elective major visceral surgery (10 ml venous
blood, collected in a chilled blood tube with Lithium
Heparin). In six patients, only one septic blood sample
was obtained since the underlying cause of sepsis was
relieved (n = 3) or patients died (n = 3). In eight patients,
a second blood sample was obtained on the fourth day
of the septic course. Overall, eight out of the evaluated
14 patients died due to sepsis. The surviving six patients
were discharged with no further 30-day mortality.
Plasma was obtained by centrifugation (1800 × g for
15 min), and the samples were subsequently stored in al-
iquots at −80 °C until further analysis. Body weight and
height for calculation of body mass index (BMI) of septic
patients was self-reported (or estimated if no self-report
was possible). Exclusion criteria were: age < 18 years,
pregnancy, rapidly progressing underlying disease such
as preoperative severe liver failure, HIV/AIDS, cardio-
genic shock as the primary underlying disease, under-
lying haematologic disease, or cytotoxic therapy given
within the previous 6 months.
Cytokine and adipocyte-derived hormone measurement
and reagents
Luminex Performance Assays for leptin, resistin, adipo-
nectin, and MCP-1 were obtained from R&D Systems
GmbH, 65205 Wiesbaden, Germany.
In brief, samples were added to a mixture of color-
coded beads and pre-coated with analyte-specific cap-
ture antibodies. Biotinylated detection antibodies specific
to the analytes of interest were added. Thereafter,
phycoerythrin-conjugated streptavidin able to bind the
biothinylated detection antibodies was added. It binds to
the biotinylated detection antibodies. Polystyrene beads
were read on a dual-laser flow-based detection instrument




All values are expressed as median with range.
When comparing data between the three blood samples,
i. e., preoperatively, septic day one and septic day four,
statistical analysis was performed using the Friedman test.
When comparing two blood samples or survivors with
non-survivors, the Wilcoxon signed rank test was used.
Analysis was performed with WinSTAT, Version 2009.1
(R. FitchSoftware) and the IBM SPSS Statistics 20.0.0
(Ehningen, Germany).
The Spearman rank-order correlation coefficient was
calculated for correlation analysis. R indicates the correl-
ation coefficient. A value of p < 0.05 was considered statis-
tically significant. Correlation coefficient values between
0.3 and 0.7 (−0.3 and −0.7) indicate a moderate, and
values between 0.7 and 1.0 (−0.7 and −1.0) indicate a
strong, positive (negative) linear relationship.
Results are presented as box-and-whisker plots. In
boxplots, the top and bottom of the rectangle represent
the 25th and 75th percentile; whiskers represent the 5th
and the 95th percentile, respectively. The line within the
rectangle represents the median.
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Results
Baseline characteristics of study participants
All 14 study participants underwent major surgical
procedures before developing severe sepsis postopera-
tively, thereby meeting the criteria defined by Bone
[13]. The duration between surgery and the occurrence
of subsequent severe sepsis/septic shock ranged from 3
days up to 1 month (median 12 days). The patients’
baseline characteristics and diseases are shown in
Table 1. Median BMI of male patients was higher com-
pared than female BMI (29 kg/m2 vs. 22 kg/m2). The
underlying causes of sepsis were anastomosis leakage
(n = 9), pneumonia (n = 3), oesophagobronchial fistula
after oesophageal resection (n = 1), and peritonitis due
to an acute perforated cholecystitis (n = 1). The median
(range) SAPS II score was of 42 (25–56) at 1 day after
diagnosis of severe sepsis or septic shock.
Adipokine levels and leukocytes in the preseptic and
septic state of patients
Adipokine levels were clearly altered in the septic state
compared with the preseptic state. For a better overview,
plasma concentrations of adiponectin, leptin, resistin,
MCP-1, whole blood leukocyte count, and C-reactive
protein are shown in Fig. 1. Compared with preoperative
blood samples, adiponectin was lowered and resistin and
leptin elevated in sepsis. Adiponectin, resistin and leptin
levels did not have a strong correlation with the SAPS II
score (r = −0.09, p = 0.38; r = 0.28, p = 0.17; r = 0.02, p =
0.48, respectively). BMI did not correlate significantly with
adiponectin in preseptic (r = 0.45, p = 0.05) and septic
states (day one: r = −0.28, p = 0.16; day four: r = −0.33, p =
0.21), but did correlate significantly with plasma leptin
levels at day four of sepsis (day zero: r = 0.24, p = 0.20; day
one: r = 0.39, p = 0.08; day four: r = 0.83, p = 0.01).
With regard to leptin and resistin, median levels were
increased in the septic state. Resistin was elevated homo-
geneously in all septic patients, while leptin levels were
elevated in 12 patients but decreased in two. MCP-1, C-
reactive protein, and white blood cell count were signifi-
cantly higher in the septic than the preseptic state. Al-
though female levels of adiponectin and leptin have been
reported to differ slightly from male levels, we found no
significant differences between the two groups.
Survival in relation to changes in adiponectin levels and
BMI
Although median adiponectin levels were lowered in the
septic state, four patients had a considerable rise of adipo-
nectin, and all of these four patients died of sepsis. Figure 2
compares adiponectin courses of patients surviving sepsis
with patients dying in septic state. Patients who survived
had significantly higher preseptic adipokine levels than
patients dying in sepsis (median: 7.22 vs. 4.40 μg/ml; p =
0.03) and showed a significant decrease at day one (me-
dian: 4.10 μg/ml; p = 0.03). In patients dying during sepsis,
the median adiponectin levels increased slightly at day
one after onset of sepsis compared with preseptic levels
(median: 4.40 vs. 4.70 μg/ml; p = 0.89).
Survival of overweight and obese patients was higher
than in weight patients. BMI of seven patients each
was ≤25 kg/m2 and BMI >25 kg/m2, respectively. In the
patient group with BMI ≤25 kg/m2, six out of seven pa-
tients died. In the group with a BMI >25 kg/m2, two out
of seven patients died. Overweight and obese patients had
a significantly higher decrease of adiponectin after onset
of sepsis than to normal weight patients (2.2 vs 0.2 μg/ml;
p = 0.04). SAPS 2 sepsis score (without GCS) at the begin-
ning of sever sepsis and septic shock was comparable in
both BMI related groups (40 vs. 42).
Discussion
The way that adipokines interact with inflammation in
sepsis has yet to be clarified. The main results of the
present study are that adiponectin levels behave incon-
sistently after onset of sepsis. Patients who survived
sepsis had significantly higher preseptic adipokine levels
than patients dying in sepsis and a significant decrease
after onset of sepsis. Further, resistin and leptin levels
are elevated in sepsis following major surgery.
Adiponectin exerts an anti-inflammatory effect. Several
mechanisms have been suggested, including direct actions
on inflammatory cells and interaction with TNF-α [5]. In
septic patients, early data suggest that plasma levels of adi-
ponectin are decreased. Whether this is a result of the dis-
ease process itself or whether patients with lower levels of
this hormone are more susceptible to develop a critical ill-
ness has not yet been described [5]. Soares et al. found,
that adipose cells are highly sensitive to oxidative stress,
Table 1 Anthropometric data of septic patients
Age (years) BMI (kg/m2) SAPS II Score at day 1
Total (n = 14) Median (min–max) 67 (51–83) 27.25 (21.5–35.5) 42 (25–56)
Female (n = 3) Median (min–max) 76 (66–83) 21.5 (21.5–22.5) 37 (35–49)
Male (n = 11) Median (min–max) 64 (51–79) 29.4 (24.4–35.5) 43 (25–56)
Survivors (n = 6) Median (min–max) 69 (54–79) 30 (22–35) 35 (34–52)
Non-survivors (n = 8) Median (min–max) 66 (51–83) 25 (22–31) 44 (25–56)
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Fig. 1 Preoperative/preseptic and postoperative/septic adipokine levels of patients (n = 14 for preseptic levels and at day 1 and n = 8 at day 4).
Analysis was performed using the Friedman test when comparing the three blood samples, i. e., preoperatively, septic day one and septic day
four (upper bar). When comparing two blood samples the Wilcoxon signed rank test was used. a Adiponectin b Leptin c Resistin d MCP-1
e Leukocytes f C-reactive protein
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with subsequent decreased adiponectin secretion and
increased lactate production, two events seen in septic
patients and involved in the development of insulin
resistance [15].
We found slightly lowered median plasma adiponectin
levels 1 day after onset of sepsis compared with presep-
tic levels. In the subgroup of patients dying during the
course of sepsis, we found lower preseptic adiponectin
concentrations compared with patients who survived
sepsis. Interestingly, in patients dying during the course
of sepsis, we found slightly increased adiponectin plasma
levels compared with preseptic levels at day one after
onset of sepsis. Walkey et al. reported that higher sys-
temic adiponectin concentrations on day one of critical
illness are associated with lower survival in critically ill
patients with respiratory failure [16]. In predicting a
28-day survival, he found adiponectin more predictive
than all other factors studied, including APACHE II
score. This could be explained by a dysfunctional
response to the stress of early critical illness of non-
survivors. In our patients, a significant initial drop in
the adiponectin levels occurred during the early phase
of sepsis in patients surviving sepsis (adiponectin levels
of surviving patients fell by 32 %). Patients dying during
the course of sepsis had an average increase of adipo-
nectin levels of 11 % after onset of sepsis compared
with preseptic levels.
Large epidemiological studies describe a correlation
between BMI and adiponectin levels. In the septic state,
we found no correlation of BMI with adiponectin levels.
In a further septic cohort, we described similar results.
Further, we reported, that adiponectin levels and insulin
demand were positively correlated during sepsis [17].
Similar results have been reported by Welter et al. [18]
in a prospective study of 21 septic patients. They de-
scribed no differences in plasma concentrations of adi-
ponectin in subgroups with a BMI above and below
30 kg/m2. Thus, the activation of the immune system
may have a greater impact on plasma adiponectin
levels than the obesity status.
Leptin is primarily involved in energy homeostasis
[19]. However, leptin also exhibits pro-inflammatory and
protective functions, and is additionally involved in the
pathogenesis of a systemic inflammatory response dur-
ing sepsis by several interactions towards T cells, mono-
cytes, and cytokine production [20]. MCP-1 is expressed
mainly by inflammatory cells and endothelial cells. The
expression level is upregulated after pro-inflammatory
stimulations. Resistin is involved in the process of in-
flammation by upregulating IL-6 and TNF-α and enhan-
cing its own activity by a positive feedback mechanism
[21]. Resistin relates to the severity of sepsis and the
degree of inflammatory response [11]. In line with
published data, we found significantly increased leptin,
MCP-1, and resistin levels after onset of sepsis. How-
ever, we did not find any correlation of BMI, sepsis
score, or any other analyzed parameter with leptin,
MCP-1, and resistin levels.
Fig. 2 Preoperative and septic adipokine plasma levels of patients surviving sepsis (dark) vs. patients dying during course of sepsis (pale)
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Our study has several limitations. The study has a small
sample size with a high mortality rate (57 %). Further, it is
known that adipokine levels fluctuate postoperatively in-
dependently of any complication [22]. Therefore, changes
in adipokine levels could not only be caused by sepsis, but
also by the operative procedure itself. Furthermore, the
beginning of sepsis after surgery differed between patients.
The period of time in which sepsis was diagnosed was 3
days up to one month after operative procedure. This may
possibly contribute to substantial bias concerning the
sepsis onset levels. In addition, the majority of patients
suffered from a malignant tumor, accompanied likewise
by changed adipokine levels [23].
Although the results of this small study require con-
firmation in a larger patient cohort, we describe the vari-
ation in adipokine levels in septic patients in relation to
patients’ preseptic levels. We found lowered adiponectin
and elevated resistin and leptin levels in septic patients.
Patients who survived sepsis had significantly higher
preseptic adipokine levels than patients dying in sepsis.
Conclusions
In severe sepsis or septic shock, adipokine plasma levels
are considerably changed compared with their preseptic
levels, with rising pro-inflammatory adipokine levels and
decreased adiponectin levels (anti-inflammatory adipo-
kine). The adipokine profile may differ between survivors
and non-survivors of subsequent severe sepsis/septic shock
following surgery.
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